In-Vivo Sample Clauses

In-Vivo. [***] Commercial Supply Agreement. If (a) NVS is Manufacturing such In-Vivo [***] Product for use outside the U.S. and (b) no Designated CMO is, at such time, able to (or within a timely manner would be capable of) Manufacture and supply such In-Vivo [***] Products, then at HMI’s request and at the appropriate time directed by the JMC, the Parties will negotiate in good faith a definitive supply agreement for NVS to supply to HMI In-Vivo [***] Products for Commercialization in the U.S. in accordance with this Agreement (“In-Vivo [***] Commercial Supply Agreement”) along with a quality assurance agreement covering quality related obligations of such supply (“In-Vivo [***] Quality Assurance Agreement”) (which In-Vivo [***] Quality Assurance Agreement will contain terms related to NVS’ rights and obligations as the Manufacturer of such In-Vivo [***] Product as well as terms related to each Party’s rights and obligations as the Regulatory Responsible Party for such In-Vivo [***] Product, including each Party’s respective review, comment, and approval rights thereunder). The In-Vivo [***] Commercial Supply Agreement and In-Vivo [***] Quality Assurance Agreement will provide for customary terms and conditions, including forecasting, ordering, delivery, manufacturing costs, termination at will rights for both Parties with reasonable advance notice periods, reasonable volume caps with a mechanism to address adjustments to such cap over time, technical criteria to be met, payment, and supply, and will be consistent with the terms of this Agreement. The transfer price paid by HMI for In-Vivo [***] Products under the In-Vivo [***] Commercial Supply Agreement shall be equal to [***]. If the Parties are unable to agree upon the terms of the In-Vivo [***] Commercial Supply Agreement, then neither Party will be obligated to enter into such agreement, and NVS will not be obligated to Manufacture In-Vivo [***] Products under the In-Vivo [***] Commercial Supply Agreement until the Parties reach agreement on the terms of such agreement.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
In-Vivo. [***] Commercialization Activities. Each Party will provide the other Party with reasonable cooperation, support, and assistance requested by the other Party, at the requesting Party’s expense, with respect to preparing such Party’s Commercialization plan for In-Vivo [***] Products in order to coordinate Commercialization with respect to such In-Vivo [***] Products throughout the Territory; provided, that any such cooperation, support, and assistance shall be limited to that permitted under Applicable Law.
Sample 1Sample 2Sample 3
In-Vivo. There few studies which have simulated in vivo tooth wear in human subjects, or aetiological tooth wear factors. This may be because in vivo simulation of tooth wear is limited by ethical considerations as tooth wear, by its very nature, is an irreversible damaging process to the dental hard tissues. However the initial surface softening is reversible and future studies may be able to simulate the initial erosion lesion which is then assessed and repaired in vivo however the assessment techniques are currently not discriminating enough for this type of research. Xxxxx et al (2006) investigated the effect of stannous fluoride and sodium fluoride toothpastes on enamel erosion in a study which simulated acid erosion, by passing diluted citric acid over healthy anterior teeth of human subjects, using a peristaltic pump. The calcium content in the citric acid applied before and after the treatment with toothpaste was measured and the authors concluded that the stannous fluoride toothpaste markedly reduced the enamel dissolution of teeth in vivo, whereas the NaF toothpaste provided no protection (Xxxxx et al., 2006). Xxxxxxxx et al (1997b) compared the effects of a xxxxx meal versus a high fat content meal taken with alcohol on GOR measured by oesophageal and oral pH and found that pathological levels of GOR were provoked by the high fat meal in 6 of the 12 subjects whereas the xxxxx meal provoked pathological levels of reflux in only two out of the twelve subjects. Moreover, there was a significantly lower pH in the anterior palatal region of the oral cavity after consumption of the high fat content meal (Xxxxxxxx et al., 1997b). If an erosive challenge were to be simulated in vivo, use of an acidic gel may reduce unnecessary exposure of enamel/dentine to damage by reducing the flow rate of an erosive challenge over tooth surfaces, which are not of interest to the measurement technique, to nil (Xxxxxxx et al., 2005). Localisation of the erosive challenge would also have the secondary advantage of allowing a split-mouth or even split-tooth design to be employed. One area which is potentially under-researched in the field of dental erosion is the role of biological factors such as saliva and the acquired dental salivary pellicle in modifying the erosive wear process in vivo (Xxxx et al., 2006b). Therefore, immediate saliva analysis could be included for in vivo models which would reduce the changes in the salivary pH that occur during storage of the saliva (Xxxxx...
Sample 1

Related to In-Vivo

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Screening 3.13.1 Refuse containers located outside the building shall be fully screened from adjacent properties and from streets by means of opaque fencing or masonry walls with suitable landscaping.

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Diagnosis For a condition to be considered a covered illness or disorder, copies of laboratory tests results, X-rays, or any other report or result of clinical examinations on which the diagnosis was based, are required as part of the positive diagnosis by a physician.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

Time is Money Join Law Insider Premium to draft better contracts faster.